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Tumor necrosis factor induces sodium retention in diabetic rats
through sequential effects on distal tubule cells
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Tumor necrosis factor induces sodium retention in diabetic rats
through sequential effects on distal tubule cells.
Background. Tumor necrosis factor (TNF) contributes to
sodium retention during diabetes. TNF selectively stimulates
sodium uptake in distal tubule cells isolated from diabetic rats,
but not in cells from control rats. We propose that distal tubule
cells are sensitized to acute effects of TNF during diabetes.
Methods. We examined acute TNF-stimulated sodium up-
take in distal tubule cells chronically cultured with exogenous
TNF and in distal tubule cells freshly isolated from diabetic rats
treated with a specific TNF inhibitor. We also tested the sodium
transport and intracellular signaling pathway underlying TNF-
induced sodium transport with pharmacologic inhibitors.
Results. Chronic TNF exposure in vitro sensitized distal
tubule cells to the acute effects of TNF in a time- and dose-
dependent manner, and TNF inhibition in vivo during diabetes
prevented distal tubule sensitization. TNF receptor expression
was equivalent in distal tubule cells from both control and
diabetic rats. In sensitized distal tubule cells, TNF-stimulated
sodium uptake was blocked by amiloride and PD098059, in-
hibitors of epithelial sodium channels and extracellular signal-
related protein kinase (ERK) activation, respectively.
Conclusion. TNF alters distal tubule sodium transport during
diabetes through consecutive chronic and acute effects. Chronic
TNF exposure leads to distal tubule sensitization that per-
mits acute TNF-induced activation of epithelial sodium channel
(ENaC). These findings are consistent with a sequential mecha-
nism by which chronic and acute TNF actions at the distal tubule
cellular level contribute to whole animal sodium retention dur-
ing diabetes.
Nephropathy contributes substantially to overall mor-
bidity and mortality in diabetic patients, and diabetic
nephropathy is the leading cause of end-stage renal dis-
ease (ESRD) in the United States [1]. Nephropathy is a
primary factor that underlies the development of hyper-
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tension in type I diabetes [1]. Albuminuria, the primary
clinical marker of diabetic nephropathy, is an indepen-
dent risk factor for ischemic heart disease, myocardial
infarction, and left ventricular hypertrophy and dysfunc-
tion [1–3]. Therefore, understanding the pathophysiology
of altered renal function is critical to the prevention and
treatment of diabetic nephropathy and its sequelae.
Urinary tumor necrosis factor (TNF) is an impor-
tant mediator of diabetic nephropathy [4]. We previ-
ously reported that TNF promotes distal tubule sodium
retention and renal hypertrophy during diabetes [4].
TNF-stimulated sodium absorption represents a signif-
icant pathologic event during diabetes because of the
deleterious effects of sodium retention. First, sodium
retention contributes to the development of hyperten-
sion in type I diabetes [1, 5–9]. Second, elevated dietary
sodium induces kidney enlargement and TGF-b expres-
sion that, in turn, mediates organ hypertrophy [10]. Re-
nal hypertrophy is common is diabetic patients and may
predict progression to ESRD [11, 12]. The finding that
sodium restriction reduces renal hypertrophy and delays
the onset of albuminuria during diabetes further supports
the importance of sodium retention in the pathogenesis
of diabetic nephropathy [13]. Since sodium retention, hy-
pertension and renal hypertrophy commonly occur in di-
abetic patients [5, 8, 9, 11, 12, 14], it is essential to discern
the pathologic changes underlying sodium retention.
The purpose of this study was to elucidate the cellular
mechanisms by which TNF alters sodium transport in dis-
tal tubule cells during diabetes. TNF stimulates sodium
uptake in distal tubule cells isolated from diabetic rats, but
not in distal tubule cells from control rats, demonstrating
that distal tubule cells are sensitized during diabetes to
the acute effects of TNF on sodium transport [4]. There-
fore, the first aim was to identify the factor causing dis-
tal tubule sensitization during diabetes. The second aim
was to determine the sodium transport and intracellu-
lar signaling mechanisms by which TNF induces sodium
uptake. The final aim of the present research was to deter-
mine whether increased receptor expression or enhanced
intracellular signaling accounts for distal tubule sensiti-
zation during diabetes.
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METHODS
Animals
Male Sprague-Dawley rats (12 weeks old) were pur-
chased from Charles River Laboratories (Wilmington,
MA, USA) and individually housed. Distal tubule cells
freshly isolated from six groups of animals were used in
uptake studies: (1) control rats (N = 6); (2) untreated di-
abetic rats sacrificed on day 10 of diabetes (N = 6); (3)
untreated diabetic rats sacrificed on day 20 of diabetes
(N = 6); (4) control rats treated with TNFR:Fc, a recom-
binant human TNF Receptor:Fc fragment fusion protein
(Immunex Corporation, Seattle, WA, USA), for 10 days
(control + TNFR:Fc) (N = 3); (5) diabetic rats treated
with TNFR:Fc through the first 10 days of diabetes (dia-
betes + TNFR:Fc 10 days) (N = 9); and (6) diabetic rats
treated with TNFR:Fc through days 10 to 20 of diabetes
(diabetes + TNFR:Fc 20 days) (N = 3). Additionally,
we isolated distal tubule cells from a separate group of
control rats (N = 3) and maintained these cells in pri-
mary culture for 10 days. Diabetes was induced by tail
vein injection of 50 mg/kg streptozotocin (STZ) (Sigma,
St. Louis, MO, USA) dissolved in 0.9% sodium chloride
(NS). Control rats were injected with an equal volume of
NS. Prior to injection, blood was drawn from the tail vein
and blood glucose was determined using the Accucheck
Advantage blood glucose-monitoring device. To verify
the onset of hyperglycemia, blood glucose was measured
again at 3 to 5 days following STZ injection. STZ-injected
rats exhibited marked hyperglycemia (control 98.3 ±
3.4 mg/dL vs. diabetic 336.9 ± 20.2 mg/dL, P < 0.05).
In rats receiving the soluble TNF antagonist TNFR:Fc,
2 mg/kg was injected subcutaneously twice weekly. To
determine if TNFR:Fc could prevent distal tubule sensi-
tization, therapy was started 1 day prior to STZ injection
and continued through day 10 of diabetes. To determine if
TNF effects in diabetes were reversible, TNFR:Fc treat-
ment was initiated on day 10 of diabetes and continued
through day 20.
Cell isolation
An in situ enzyme digestion procedure previously de-
scribed was used to isolate distal tubule cells [15]. Dis-
tal tubule cells were incubated with a primary antibody
to Tamm-Horsfall protein covalently attached to a mag-
netic particle (Polysciences Inc, Warrington, PA, USA)
and disassociated from other cell types by immuno-
magnetic separation [16]. Distal tubule cells isolated
by this procedure exhibited characteristic distal tubule
transport pathways, including calcitonin and parathy-
roid hormone-stimulated calcium transport [17, 18],
amiloride and chlorothiazide-sensitive sodium uptake
[19], and phenylephrine-stimulated sodium transport [20]
(Table 1).
Table 1. Comparison of sodium and calcium transport pathways in
freshly isolated and cultured primary distal tubule cells
Freshly isolated Cultured primary
distal tubule distal tubule
cells cells
Sodium uptake
Basal 256.6 ± 5.7 252.2 ± 8.3
Phenylephrine 408.6 ± 3.4a 426.8 ± 0.9a
Calcium uptake
Basal 2.7 ± 0.1 2.6 ± 0.1
Parathyroid hormone 4.2 ± 0.2a 4.1 ± 0.1a
Sodium and calcium uptake was measured in distal tubule cells freshly
isolated from control rats or in primary distal tubule cells cultured in 5 mmol/L
glucose media for 10 days. Basal uptake represents sodium or calcium uptake
in the absence of any exogenous inhibitors/agonists. Cells were treated with
phenylephrine (1 lmol/L) or parathyroid hormone (10 nmol/L) to verify that the
cell populations exhibited these characteristic distal tubule sodium and calcium
transport pathways. No significant differences were observed between freshly
isolated or cultured primary distal tubule cells.
aP < 0.05 versus basal.
Cell culture
Freshly isolated distal tubule cells were established as
primary cultures in minimum essential media (MEM)
containing 5 mmol/L glucose supplemented with 10% fe-
tal calf serum and penicillin/streptomycin. Cultured pri-
mary distal tubule cells exhibited the same characteristic
transport pathways as freshly isolated distal tubule cells
(Table 1), showing that the distal tubule phenotype was
not altered during cell culture. Some distal tubule cells
were cultured either in high-glucose (30 mmol/L) media
or in the presence of TNF (Research Diagnostics, Inc.,
Flanders, NJ, USA). Media was changed daily through-
out the experiment to ensure steady levels of these addi-
tional components. In control experiments, TNF was not
detectable in the media alone, as measured by enzyme-
linked immunosorbent assay (ELISA) (OptEIATM Rat
TNF Set) (Pharmingen, San Diego, CA, USA), and
the cultured cells did not secrete TNF into the media.
When exogenous TNF was added to the media, TNF
levels, determined by ELISA, remained constant over
24 hours.
Uptake assay
Freshly isolated distal tubule cells were washed three
times following magnetic separation and resuspended in
incubation buffer (140 mmol/L NaCl, 5 mmol/L KCl,
1 mmol/L CaCl2, 1 mmol/L MgCl2, 28 mmol/L HEPES,
18 mmol/L Tris base, and 10 mmol/L glucose, pH 7.4,
Osm 295). Cultured primary distal tubule cells were
trypsinized, washed three times, and resuspended in incu-
bation buffer. A rapid filtration technique described pre-
viously was used to measure uptake of 22Na+ or 45Ca++
into suspended distal tubule cells [21]. Distal tubule cells
were incubated at 37◦C in the presence of TNF for
15 minutes prior to the addition of 22Na+ or 45Ca++.
Tracer uptake was terminated after 1 minute by rapid
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addition of ice-cold iso-osmotic buffer and the cells were
filtered onto Whatman GF/C filters (Clifton, NJ, USA)
using a Millipore 12-port manifold (Billerica, MA, USA).
Control experiments indicate that tracer uptake is linear
for 2 minutes. Nonspecific binding of 22Na+ and 45Ca++
to filters and cells was determined and subtracted to
calculate uptake. Uptake was normalized to total cellu-
lar protein, quantified by Pierce bovine serum albumin
(BSA) Protein AssayTM (Pierce, Rockford, IL, USA).
C8-ceramide (Biomol, Plymouth Meeting, PA, USA) was
used as a cell-permeable ceramide analogue to replicate
the effect of endogenous ceramide [22].
Saturation binding
Distal tubule cells were isolated and homogenized, and
membrane protein fractions were isolated by centrifu-
gation. Membranes were incubated with increasing con-
centrations of 125I-TNF (1.0 × 10−12.5 to 10−10 mol/L)
(Perkin-Elmer Life Sciences, Inc., Boston, MA, USA)
in phosphate-buffered saline (PBS)/albumin for 2 hours
at 4◦C. One-hundred-fold excess nonradioactive TNF
was added to some membrane fractions to determine
nonspecific binding. Following the incubation period,
the membranes were washed in ice-cold Tris buffer
(10 mmol/L, pH 7.4), collected on filter paper using a
cell harvester, and the filters were placed in scintillation
vials and counted. Total receptor number (Bmax) and Kd
were determined using GraphPad Prism software’s sat-
uration binding module. The experiment was repeated
three times and mean ± SEM was determined. The
Kd values calculated from these experiments, shown in
Table 3, are equivalent with published observations in
other cell types [23].
Statistical analysis
For uptake experiments using freshly isolated distal
tubule cells and cultured primary distal tubule cells,
the sample size provided in the figure legend repre-
sents the number of rats from which cells were de-
rived. All of the experimental conditions in the up-
take assays were tested in triplicate on each individual
sample. Statistical significance was determined using
analysis of variance (ANOVA) followed by Student-
Newman–Keuls multiple comparisons test. P < 0.05 was
considered significant.
RESULTS
Distal tubule sensitization is independent
of glucose levels
Because urinary glucose is increased throughout the
first 20 days of diabetes [4], we hypothesized that chronic
exposure to high glucose could induce distal tubule sensi-
tization. To test this hypothesis, we isolated distal tubule
cells from control rats and cultured them for 4 or 10 days
in high-glucose (30 mmol/L) media. Neither basal (de-
fined herein as sodium transport in the absence of exoge-
nous compounds in the acute sodium uptake assay) or
TNF-stimulated sodium transport was altered following
4 or 10 days of culture in high-glucose media (data not
shown).
Chronic TNF exposure sensitizes distal tubule cells
Urinary TNF excretion is elevated in diabetic rats [4,
24]. We hypothesized that elevated TNF levels under-
lie distal tubule sensitization. To test the hypothesis that
chronic TNF exposure sensitizes distal tubule cells, we
cultured primary distal tubule cells isolated from control
rats in the presence of TNF. Since distal tubule sensiti-
zation is evident following 10 days of diabetes [4], we
treated cultured primary distal tubule cells with differ-
ent TNF concentrations for 10 days. Following 10-day
exposure to TNF, we removed the media, resuspended
the cells in incubation buffer, and measured sodium up-
take. Basal sodium transport was not altered by chronic
TNF at any of the concentrations tested (Fig. 1A). Expo-
sure to 0.1 ng/mL TNF for 10 days did not induce distal
tubule sensitization; however, chronic exposure to both
1 and 10 ng/mL TNF sensitized distal tubule cells, since
acute TNF significantly stimulated sodium uptake above
the basal level (Fig. 1A).
To test the hypothesis that distal tubule sensitization
by chronic TNF exposure is time-dependent, we cultured
distal tubule DT cells from control rats in the presence
of 10 ng/mL TNF for 4 or 10 days. Chronic TNF did
not affect basal sodium transport at either 4 or 10 days
(Fig. 1B). Four days of exposure to 10 ng/mL TNF failed
to sensitize distal tubule cells (Fig. 1B), but 10 days of
chronic TNF induced distal tubule sensitization since,
acute TNF significantly stimulated sodium entry by 33%
above basal levels (Fig. 1B).
In vivo TNF inhibition prevents distal tubule
sensitization during diabetes
The previous results demonstrate that chronic TNF ex-
posure sensitizes cultured distal tubule cells. To test the
hypothesis that TNF mediates distal tubule sensitization
in vivo during diabetes, we treated diabetic rats with the
soluble TNF receptor fusion protein, TNFR:Fc. This pro-
tein binds TNF and significantly decreases urinary TNF
excretion in diabetic rats [4]. TNFR:Fc administration in
vivo significantly reduced acute TNF-stimulated sodium
uptake in distal tubule cells freshly isolated from diabetic
+ TNFR:Fc 10-day rats (Fig. 2). TNFR:Fc treatment did
not alter either TNF-stimulated sodium transport in dis-
tal tubule cells freshly isolated from control + TNFR:Fc
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Fig. 1. Tumor necrosis factor (TNF) sensitizes distal tubule cells in a
dose- and time-dependent manner. (A) Distal tubule cells isolated from
control rats were cultured in the presence of different TNF concen-
trations for 10 days. Acute TNF (10 ng/mL)-stimulated sodium (Na)
transport was measured following the chronic TNF treatment period
and compared to basal sodium uptake. (B) Distal tubule cells isolated
from control rats were exposed to chronic 10 ng/mL TNF for 4 or 10 days
in culture prior to measurement of acute TNF (10 ng/mL)-stimulated
sodium transport. The acute effect of TNF on sodium uptake in distal
tubule cells freshly isolated from control rats (0 days in culture) is shown
for comparison. Bars and symbols represent mean ± SEM of N = 3.
∗P < 0.05 versus basal.
rats (data not shown) or basal sodium transport in distal
tubule cells from any of the groups tested.
In vivo TNF inhibition reverses distal tubule
sensitization during diabetes
We also tested the hypothesis that TNF inhibition in
vivo during diabetes would reverse distal tubule sensi-
tization by initiating TNFR:Fc treatment after 10 days
of uncontrolled diabetes. Following 10 days of TNFR:Fc
therapy (day 20 of diabetes), we isolated distal tubule
cells and measured acute TNF-stimulated sodium up-
take. TNFR:Fc administration in vivo significantly re-
duced TNF-stimulated sodium uptake in distal tubule
cells freshly isolated from diabetic + TNFR:Fc 20-day
rats by 65% compared to distal tubule cells from un-
treated diabetic 20-day rats (Fig. 2).
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Fig. 2. Tumor necrosis factor receptor fragment (TNFR:Fc) prevents
and reverses distal tubule sensitization in vivo during diabetes. Diabetic
(Diab) rats were treated with TNFR:Fc for the first 10 days or from
days 10 to 20 of diabetes prior to distal tubule cell isolation. Sodium
(Na) uptake was performed on freshly isolated distal tubule cells. Bars
represent mean ± SEM of N = 3 (Diab + TNFR:Fc, day 20), N = 6
(Diab, day 10 and 20), or N = 9 (Diab + TNFR:Fc, day 10). ∗P < 0.05
versus Diab + TNF.
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Fig. 3. Tumor necrosis factor (TNF) stimulates sodium (Na) uptake via
epithelial Na channels (ENaC). Distal tubule cells were freshly isolated
on day 10 of diabetes and exposed to TNF (10 ng/mL) ± chloroth-
iazide (CTZ) (100 lmol/L) or amiloride (Amil) (1 lmol/L), which
inhibit sodium chloride cotransporters and ENaC, respectively. Bars
depict TNF-stimulated sodium uptake above the basal level and repre-
sent mean ± SEM of N = 3. ∗P < 0.05 versus TNF alone.
TNF stimulates sodium uptake through epithelial
sodium channels (ENaC)
The second aim of this research was to identify the cel-
lular mechanisms mediating TNF-induced sodium trans-
port. Distal tubule cells take up sodium primarily through
thiazide-sensitive sodium-chloride cotransporters (TSC)
and ENaC [19]. To determine whether TNF activates
TSC or ENaC to stimulate sodium uptake, we treated
distal tubule cells freshly isolated from diabetic rats with
TNF ± chlorothiazide (CTZ) (100 lmol/L) or amiloride
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Fig. 4. Tumor necrosis factor (TNF)-induced sodium (Na) uptake re-
quires extracellular signal-regulated protein kinase (ERK) activation.
Distal tubule cells freshly isolated from rats following 10 days of di-
abetes were acutely exposed to TNF ± PD98059 (PD) (10 lmol/L),
Calphostin-C (Cal-c) (1 lmol/L), or N-oloeylethanolamine (NOE) (1
lmol/L) for 15 minutes. Bars represent mean ± SEM of N = 3. ∗P <
0.05 versus TNF.
(1 lmol/L), inhibitors of TSC and ENaC, respectively.
CTZ treatment did not affect TNF-stimulated sodium
uptake, whereas amiloride abolished sodium transport
in response to TNF (Fig. 3).
Extracellular signal-regulated protein kinase (ERK)
activation mediates TNF effects in distal tubule cells
from diabetic rats
In addition to identifying the sodium transport mech-
anism activated by TNF, we also investigated the in-
tracellular signaling pathway underlying TNF-stimulated
sodium uptake. Known TNF signaling pathways include
activation of protein kinase C (PKC) [25], ceramidase
[26, 27], and ERK [28]. Therefore, we examined the role
of these pathways using pharmacologic inhibitors. TNF
increased sodium uptake in distal tubule cells isolated
from diabetic rats by 45% above the basal rate (Fig. 4).
Specific inhibition of ERK activation with PD098059 [29]
fully inhibited this response to TNF (Fig. 4). Inhibition
of PKC with Calphostin-C [30] or ceramidase with N-
Oleoylethanolamine [31], at concentrations that block
stimulated calcium transport in distal tubule cells (un-
published observations), failed to prevent TNF-induced
sodium transport (Fig. 4).
TNF receptors are not up-regulated during diabetes
The final aim of this study was to identify the mech-
anism of distal tubule sensitization. Our data show that
chronic TNF exposure induces distal tubule sensitization
in vitro and in vivo during diabetes. Since TNF is capable
of up-regulating its own receptor expression [32, 33], we
hypothesized that TNF-induced distal tubule sensitiza-
tion is due to increased TNF receptor expression. To test
this hypothesis, we quantified TNF receptor expression
Table 2. Distal tubule tumor necrosis factor (TNF) receptor
expression is not altered during diabetes
Control Diabetic
TNF receptor expression 1.65 ± 0.75 1.13 ± 0.43
fmol/mg protein
Kd 1.46 × 10−11 1.50 × 10−11
Membrane fractions were isolated from distal tubule cells from control and
diabetic 10-day rats and incubated with increasing concentrations of 125I-TNF to
determine TNF receptor expression.
0
250
300
400
350
N
a 
up
ta
ke
,
n
m
ol
 m
in
–
1 m
g 
pr
ot
ei
n–
1
Basal TNF Ceramide
NS
*# *#
*
Control
Diab 10d
Fig. 5. Distal tubule cells are sensitized to the effect of C8-ceramide
during diabetes. Distal tubule cells freshly isolated from control or dia-
betic (Diab) (day 10) rats were exposed to tumor necrosis factor (TNF)
or C8-ceramide for 15 minutes. Bars represent mean ± SEM of N =
4 (ceramide) or N = 6 (basal, TNF). ∗P < 0.05 versus basal #P < 0.05
versus control. NS is not significant versus basal.
in distal tubule cells isolated from control and diabetic
rats by ligand binding. TNF receptor expression was not
significantly altered during diabetes (Table 2).
Augmented intracellular signaling underlies distal
tubule sensitization
TNF receptor up-regulation did not mediate sensitiza-
tion; we hypothesized that augmented intracellular sig-
naling accounts for distal tubule sensitization. To test this
hypothesis, we treated cells with exogenous C8-ceramide,
which bypasses TNF receptors to directly activate intra-
cellular signaling [28, 34]. In diabetic rat distal tubule
cells, TNF and C8-ceramide enhanced sodium uptake
equivalently (Fig. 5). PD098059 (10 lmol/L) prevented
sodium uptake in response to C8-ceramide (268.4 ±
5.5 nmol/min/mg protein; P < 0.05 vs C8-ceramide),
showing that, like TNF, C8-ceramide activates the ERK
pathway to enhance sodium transport. In contrast, C8-
ceramide, but not TNF, increased sodium transport in
distal tubule cells from control rats. However, the magni-
tude of the C8-ceramide effect was significantly lower in
distal tubule cells from control rats than in cells from dia-
betic rats, providing evidence of augmented intracellular
signaling in distal tubule cells during diabetes.
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Table 3 Distal tubule sodium transport mechanisms are not
up-regulated during diabetes
Sodium uptake
nmol min−1 mg protein −1
Treatment Control Diabetic
Basal 256.6 ± 5.7 257.6 ± 7.4
Chlorothiazide 198.8 ± 13.6a 192.1 ± 17.3a
Amiloride 173.3 ± 9.9a 168.6 ± 22.8a
Phenylephrine 408.6 ± 3.4a 399.2 ± 4.0a
Sodium uptake was measured in distal tubule cells isolated from control and
diabetic rats following 15 minutes’ exposure to chlorothiazide (100 lmol/L),
amiloride (1 lmol/L), or phenylephrine (1 lmol/L) and compared to the basal
rate of sodium transport. Data represent mean ± SEM for N = 4–6. No statis-
tically significant differences were observed between distal tubule cells isolated
from control and diabetic animals.
aP < 0.05 versus basal.
To determine whether distal tubule sensitization is spe-
cific to TNF receptor signaling or generalized to include
other receptor-mediated sodium uptake pathways, we
measured phenylephrine (PHE) (1 lmol/L)-stimulated
sodium transport in distal tubule cells. We chose PHE
because it activates sodium uptake in distal tubule cells
through a receptor activated signaling pathway distinct
from that of TNF [20]. PHE-stimulated sodium transport
was equivalent in distal tubule cells from control and di-
abetic rats (Table 3).
DISCUSSION
The role of TNF in the pathogenesis of diabetic
nephropathy has become increasingly clear. Hasegawa
et al [35] first showed that glomerular basement mem-
branes isolated from diabetic rats stimulate TNF pro-
duction in isolated macrophages. This effect is reduced
by aminoguanidine, which prevents the formation of
advanced glycation end products (AGEs). Nakamura
et al [36] demonstrated elevated TNF mRNA levels in
glomeruli from diabetic rats, and Sugimoto et al [37]
showed that AGEs contribute to increased TNF protein
expression in diabetic rat glomeruli. We found that uri-
nary TNF excretion is increased in diabetic rats prior to
the onset of albuminuria [4], a finding recently confirmed
by Kalantarinia, Awad, and Siragy [24]. Additionally, we
demonstrated that TNF contributes to sodium retention,
by enhancing sodium transport in the distal tubule, and
renal hypertrophy [4].
Clinical studies also support a role for TNF in the
progression of diabetic nephropathy. Several investiga-
tions document elevated serum TNF concentrations in
diabetic patients compared to controls [38–40]. Serum
TNF concentrations are correlated with urinary pro-
tein excretion in diabetic patients [41]. Furthermore, the
nonspecific TNF inhibitor pentoxifylline reduces both
serum TNF levels and albuminuria in diabetic patients,
and reduced proteinuria is significantly correlated with
decreased serum TNF concentration [41]. These clin-
ical findings suggest that TNF contributes to diabetic
nephropathy in patients. Therefore, additional insight
into the mechanisms by which TNF promotes diabetic
nephropathy in animal models is likely to improve the
prevention and treatment of nephropathy in diabetic
patients.
The present study enhances our understanding of the
renal effects of TNF during diabetes. We identify TNF
as the factor underlying distal tubule sensitization in
vivo during diabetes and characterize the dose and time-
dependent nature of distal tubule sensitization by TNF.
We show that TNFR:Fc therapy, which reduces urinary
TNF excretion in diabetic rats [4], both prevents and re-
verses distal tubule sensitization in vivo during diabetes
(Fig. 2). These findings provide compelling evidence that
urinary TNF sensitizes distal tubule cells in vivo during di-
abetes and support the concept that altered distal tubule
sodium transport underlies whole animal sodium reten-
tion in diabetic rats.
Our data support the conclusion that TNF has two dis-
tinct effects on distal tubule cells. The first effect, distal
tubule sensitization, occurs slowly and was only signifi-
cant after more than 4 days of TNF exposure (Fig. 1). In
addition, distal tubule sensitization in response to TNF
dissipated slowly over several days (unpublished observa-
tions). Although this effect reverses slowly, chronic TNF
exposure does not cause a sustained increase in basal
sodium transport. Sensitized distal tubule cells trans-
ferred from cell culture to suspension for the sodium up-
take assay (approximately 30 minutes) exhibit the same
basal rate of sodium transport as nonsensitized cells. The
second effect, stimulation of sodium uptake, transpires
rapidly following acute exposure to TNF, since sensitized
distal tubule cells exhibit increased sodium transport in
response to 15-minute exposure to TNF (Fig. 1). Both
chronic sensitization and acute TNF signaling are re-
quired for stimulated sodium uptake in response to TNF;
either alone is not sufficient to sustain enhanced sodium
transport. Although these two effects may be less dis-
tinct in vivo during diabetes, our findings suggest that the
continuous presence of TNF is necessary for sustained
sodium uptake leading to sodium retention during dia-
betes. This idea implies a persistent source of urinary TNF
in vivo in diabetes, which is consistent with our previous
finding of elevated urinary TNF excretion throughout the
first 20 days of diabetes [4].
Sensitization essentially primes distal tubule cells for
the acute effect of TNF. Distal tubule sensitization prob-
ably requires gene transcription and/or new protein syn-
thesis, given the long time necessary for the effect. TNF
stimulates sodium transport via ENaC, since amiloride
abolished the acute effect of TNF (Fig. 3). Therefore, in-
creased ENaC expression could account for distal tubule
sensitization. However, basal ENaC activity (in the ab-
sence of acute TNF) was equivalent in distal tubule cells
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from control and diabetic 10-day rats (Table 3), suggest-
ing that expression of ENaC is not increased in sensitized
distal tubule cells. Additionally, TNF receptor expression
was unaltered during diabetes (Table 2), ruling out TNF
receptor up-regulation as a mechanism of distal tubule
sensitization. The finding that distal tubule cells are also
sensitized to the effects of C8-ceramide (Fig. 5), which by-
passes the TNF receptor to directly activate intracellular
signaling, suggests that augmented intracellular signaling
underlies distal tubule sensitization. Both TNF and C8-
ceramide appear to be dependent on ERK activation, be-
cause sodium uptake in response to each was abolished
by the specific inhibitor of ERK activation, PD098059
(Fig. 4). Up-regulation of the signaling proteins connect-
ing the TNF receptor to ERK activation or proteins
linking ERK to ENaC activation is a plausible mechanism
underlying distal tubule sensitization by chronic TNF ex-
posure. However, any such changes should be specific to
the acute TNF signaling pathway, because distal tubule
sensitization appears to be specific to this pathway. Al-
though distal tubule cells are sensitized to the acute ef-
fects of both TNF and C8-ceramide during diabetes, the
cells are not sensitized to acute effects of PHE, an a1-
adrenergic receptor agonist. This finding suggests that
distal tubule sensitization by chronic TNF exposure is
not a general up-regulation or sensitization of receptor
and signaling pathways that regulate sodium transport.
Distal tubule sensitization was independent of glucose
level; high glucose (30 mmol/L) culture conditions did not
induce distal tubule sensitization (data not shown). These
data show that distal tubule sensitization is not due to a
direct effect of elevated glucose on distal tubule cell func-
tion and implies that distal tubule cells do not produce
TNF in response to high glucose. Although high glucose
did not directly sensitize distal tubule cells, high glucose
may indirectly contribute to distal tubule sensitization
in vivo by inducing TNF production in other cell types.
Morohoshi et al [42] demonstrate that 30 mmol/L glucose
stimulates TNF production from cultured macrophages.
Thus, macrophages represent a potential source of TNF
in vivo in response to high glucose. Alternatively, high
glucose concentrations leading to AGE formation could
augment TNF production. This idea is consistent with
findings that both glomerular AGE and TNF levels are re-
duced by aminoguanidine treatment [37]. TNF produced
from other cell types in response to hyperglycemia in vivo
could subsequently lead to distal tubule sensitization.
The time frame associated with the effect of TNF on
distal tubule cells is unusual compared to other hor-
monal regulators of sodium transport. Most, if not all,
hormones that affect sodium absorption do so within a
relatively short timeframe (minutes to hours). This mech-
anism of TNF action may be applicable to investigation
of the effects of other cytokines or hormones on renal
function and should be considered as a possible mecha-
nism when evaluating new agents that regulate sodium
transport.
CONCLUSION
The results presented provide evidence that increased
renal TNF production during diabetes leads to enhanced
sodium absorption in the distal tubule. Chronic TNF ex-
posure sensitizes distal tubule cells in a time- and dose-
dependent manner, enabling TNF to acutely stimulate
sodium uptake. This phenomenon can be reproduced
in vitro by chronic treatment with exogenous TNF and
prevented in vivo during diabetes with TNF inhibition.
In sensitized distal tubule cells, TNF stimulates sodium
transport through ENaC via activation of the ERK sig-
naling pathway. These findings are consistent with the
known role of TNF in sodium retention during diabetes
and elucidate the cellular mechanism underlying TNF-
induced sodium retention. Discerning these mechanisms
enhances our knowledge about pathologic renal changes
during diabetes and provides novel insight into therapies
that may prevent or reverse diabetic nephropathy.
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